PMS Registry
Company Name
Johnson & Johnson Pte Ltd
Protocol Number
Title of Study
A multicenter, prospective, longitudinal registry of patients with prostate cancer in Asia
Primary Objective
This observational registry aims to document PC disease in routine clinical practice in Asia, regardless of treatment used. The objectives of this registry are:
1.To document PC management including diagnosis, prognosis, treatment, and care in real-world practice.
2.To observe the clinical progression and outcomes of PC, such as overall survival (OS), PC-related mortality (PM), metastasis-free survival (MFS), progression-free survival (PFS), and time to PSA progression (TTPP).
3.To examine considerations of, duration of, and adherence to PC treatments.
4.To assess PROs on HRQoL.
5.To examine the association of multiple risk factors with disease progression.
Number of Sites
Taiwan:2 ; Global:38
Period of Study
From:September 9, 2015 to:September 15, 2020
Number of Patients
IRB Approval Date
NTUH: October 6, 2015
KSVGH: September 10, 2015
Publication Plan / Date
January 3, 2021